Taken together, the innately different responses to either chemotherapy or targeted therapy between the HR‐positive, HER2‐positive, and HR‐negative, HER2‐positive breast cancer calls for more precise and complete breast cancer proliferation blockade. Here, ERBB2 is linked to breast cancer.